|
Real-time Estimate
Cboe BZX
15:57:46 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 693.72 USD | +2.96% |
|
+4.09% | +22.77% |
| 10-23 | Medpace's Bookings, Pre-Backlog Trends Support Growth Outlook, UBS Says | MT |
| 10-23 | UBS Adjusts Price Target on Medpace to $700 From $673, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 18.85B | |||||
| 63.48B | |||||
| 54.55B | |||||
| 53.59B | |||||
| 44.75B | |||||
| 41.62B |
Select your edition
All financial news and data tailored to specific country editions
